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Abstract  
Background: Nausea and vomiting are common symptoms in palliative care. Haloperidol is often 
used as an antiemetic in this context though direct evidence supporting this practice is limited.    
Objective: To evaluate the efficacy and clinical use of haloperidol as an antiemetic in non-
palliative care contexts to inform practice.    
Methods: Rapid review of i) published evidence to supplement existing systematic reviews, and 
ii) practical aspects affecting the use of haloperidol including formulations and doses that are 
commonly available internationally.  
Results: In nausea and vomiting related to cancer treatment, haloperidol was superior to control 
in two small studies. In post-operative nausea and vomiting (PONV), two randomised controlled 
trials found treatment with haloperidol comparable to ondansetron. In palliative care, an 
observational study found a complete response rate of 24% with haloperidol (1 in 4 patients) 
which would be consistent with an NNT of 3 to 5 derived from PONV.  
Conclusion: There remains insufficient direct evidence to definitively support the use of 
haloperidol for the management of nausea and vomiting in palliative care. However, generalising 
evidence from other clinical contexts may have some validity.  
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Introduction 
The butyrophenone haloperidol was first licensed as an antipsychotic in 1958
1
.  Early studies 
also showed that haloperidol effectively protected against apomorphine-induced emesis
2
.  
Subsequently the anti-emetic properties of haloperidol have been demonstrated in a plethora of 
animal studies.  These include efficacy of haloperidol against dopamine agonist-induced emesis 
in dogs
3, 4 
and ferrets
5
.  These effects have led to its use in the management of nausea and 
vomiting in palliative care; indeed, haloperidol is internationally considered to be one of the 
essential medications in palliative care
6
. 
Haloperidol acts as an antagonist and has strong affinity for the dopamine D2 receptor, 
accounting for its antipsychotic activity.  The emetogenic process involves the chemoreceptor 
trigger zone (CTZ) in the brain.  This is the site of action of most anti-emetic drugs and the key 
neurotransmitters involved in the emetic process are dopamine, serotonin and substance P
7
.  This 
region is particularly dopamine-rich; therefore the antagonism of dopamine D2 receptors by 
haloperidol in the CTZ is a generally accepted mechanism of reducing nausea and vomiting
8
. 
Although haloperidol is often prescribed for the management of nausea and vomiting in 
palliative care, systematic reviews have shown the lack of definitive studies confirming its 
efficacy
9, 10, 11
.  In the most recent systematic review (2009) Perkins and Dorman
11
 found no 
RCTs and the identified 26 non-RCT studies were all excluded. Keeley, in ‘Clinical Evidence’12 
cites the 2001 systematic review by Critchley
9
 in his summary statement that: “Although 
haloperidol is almost universally used for nausea, especially where the cause is chemical or 
metabolic, there is no RCT evidence that it is beneficial. However, there is consensus, based 
largely on case series, that haloperidol is an effective antiemetic for chemical and metabolic 
causes of nausea and vomiting, such as opioid-induced nausea, renal failure, and 
hypercalcaemia”. 
The aim of this rapid review was to bring together published evidence on the efficacy, 
safety and clinical use of haloperidol as an anti-emetic to inform its use in a palliative care 
context. 
 
Methods 
Data search method 
Searches were undertaken of MEDLINE, PsycInfo, EMBASE, Web of Science and the Cochrane 
library covering the period from November 1
st
 2011 to March 1
st
 2012.  The basic search strategy 
was (“haloperidol”) AND (“nausea” OR “vomiting”), modified for each database.  The reference 
lists of studies that were retrieved for the detailed evaluation were hand-searched for any 
additional relevant citations. 
 
Setting and types of intervention 
We included studies where haloperidol was used to treat nausea or vomiting (alone or in addition 
to other agents) including any dose of haloperidol, via any route, over any duration of follow up.  
All types of studies or trials were included from the following settings – cancer, chemotherapy, 
radiation, postoperative nausea and vomiting (PONV). 
 
Data collection and analysis 
We judged the potential relevance of studies based on their titles and abstracts, and obtained 
studies which we anticipated might meet the inclusion criteria.  We read these to assess 
suitability for inclusion. 
 
Use of haloperidol in clinical practice 
Haloperidol preparations available in the UK were identified from the British National 
Formulary and their Summaries of Product Characteristics (SPC) were obtained from the 
Electronic Medicines Compendium (eMC) and reviewed for licensed indications.  
 
Results 
Chemotherapy and Radiotherapy 
Büttner et al.
13
 found that no conclusions could be drawn from their meta-analysis of the efficacy 
of haloperidol in treating nausea and vomiting induced by chemotherapy or radiation treatment.  
In a small chemotherapy trial it was found that haloperidol was superior to benzquinamide in the 
prevention of acute vomiting, with patients preferring haloperidol for emesis induced by nitrogen 
mustard (67% vs. 16%; 17% had no preference) or cis-platinum (78% vs. 22%)
14
.  In a radiation 
therapy trial, haloperidol was superior to placebo in the prevention of delayed vomiting with 
96% of patients taking haloperidol reporting reduced vomiting, compared to 20% of patients 
receiving placebo
15
.  There have not been any clinical studies since the meta-analysis of Büttner 
et al.
13
 to suggest the efficacy of haloperidol for the management of nausea and vomiting induced 
by chemotherapy or radiation treatment. 
 
Post-operative nausea and vomiting 
The anti-emetic efficacy of haloperidol (1 or 2 mg) was shown to be strong and comparable to 
other anti-emetics that are used for the prevention and treatment of post-operative nausea and 
vomiting [PONV]
13,  16
.  The Büttner meta-analysis found efficacy at doses between 0.5 and 4 mg 
haloperidol, but not for 0.25 mg; the relative benefit to PONV with haloperidol compared with 
placebo was 1.26 to 1.51 (number needed to treat [NNT], 3.2 to 5.1). Two randomised, double-
blinded studies have since compared haloperidol (i.v. administration) to ondansetron (4 mg) for 
PONV prophylaxis in a mixed surgical population.  In Lee et al.
17
, patients on 2 mg haloperidol 
or 4 mg ondansetron reported a low incidence of PONV (<30%, the expected incidence of 
PONV in this study was 60%) within 24 hours post-operatively with no significant difference 
between the two drugs. In the second RCT, Rosow et al.
18
, showed that haloperidol 1 mg had 
similar efficacy to ondansetron 4mg for prevention of PONV, with 78.2% and 76.8% of patients 
having complete response, defined by no nausea or vomiting. A randomised double-blinded 
study in women found treatment with 1 mg haloperidol reduced the incidence of PONV 0-4 
hours after surgery from 49% of patients in the saline group to 24%, an effect comparable with 
0.625 mg droperidol (23%); furthermore, 4-24 hours post-operatively haloperidol treatment 
reduced the incidence of PONV from 30% of patients in the saline group to 11%, this significant 
reduction in PONV was not observed in the droperidol group (14%)
19
. 
Low doses of haloperidol have also been shown to be efficacious in combination with 
other anti-emetics to prevent PONV. A randomised blinded trial found that the cumulative 
incidence of vomiting in a group combining 1.5 mg haloperidol and 8 mg dexamethasone was 
significantly lower at 24 hours (RR 0.54, 95% CI: 0.31-0.86) post-operatively than with 
dexamethasone alone
20
. However, the incidence of nausea was not different between the two 
study arms. A randomised double-blind study combining 2 mg haloperidol and 4 mg ondansetron 
found that the combined treatment group had a significantly higher (p<0.05) complete response 
rate at 24 hours after surgery (79%) compared to haloperidol alone (61%) and ondansetron alone 
(62%); patient satisfaction scores were also significantly (p<0.05) higher in the combined group 
(8.3 ± 1.8) than in the haloperidol alone group (7.0 ± 2.4) and ondansetron alone group (7.2 ± 
2.5; Feng et al., 2009)
21
. In another randomised double-blind study a combination of 1 mg 
haloperidol in addition to 4 mg ondansetron in a mixed surgical population produced more 
complete responders than ondansetron alone (76.2% vs 59.2%)
22
.  In addition, Chu et al
23
 found 
in a randomised double-blind study in women, that the incidences of PONV in the 2 mg 
haloperidol (37%), 1.25 mg droperidol (36%) and 5 mg dexamethasone (38%) groups were all 
significantly lower than the incidence of PONV in the saline group (65%).  Moreover, the 
combination of 2 mg haloperidol and 5 mg dexamethasone had the lowest incidence of PONV 
(19%) and was significantly lower than the other single treatment groups
23
. 
 
Cancer-related nausea and vomiting 
A recent open-label uncontrolled trial did suggest efficacy of haloperidol as an anti-emetic in the 
management of nausea and vomiting not related to anti-cancer treatment in patients with 
cancer
24
.  The endpoint was adjusted to assess the patient response at day 2 of a 5-day study due 
to low recruitment rate and high attrition. At day 2, 8 out of 33 patients (24%; 95% confidence 
interval [CI]: 10%-39%) had complete control of nausea and vomiting and 12 had partial control 
(36%; 95% CI: 20%-53%), giving an overall response rate of 61% (95% CI: 44%-77%)
24
  The 
authors report that the results were similar to those seen for methotrimeprazine in a previous 
study using the same methodology
25
.  In this study, at day 2, 33/53 (62%) patients showed some 
improvement in nausea and vomiting, and at day 5, improvement was seen in 20/34 (58%) 
patients. 
 
Practical use of haloperidol in palliative care 
Based on their meta-analysis, Büttner and colleagues conclude that the antiemetic efficacy of 
haloperidol in the reviewed studies was reached at doses of 1-4 mg once or twice daily when 
administered orally or by i.m. injection
13
.  Easily and accurately administered small doses of 
haloperidol are particularly important in palliative care because of some patients’ difficulties in 
swallowing.  Haloperidol is available as tablets (0.5, 1.5, 5, 10, 20 mg, as oral solution (Haldol 2 
mg/mL; Dolpin 5mg/5mL & 10mg/5mL) and for i.m. injection (5 mg/mL).  The licensed 
indications of haloperidol products vary, and some but not all of the oral solutions list ‘nausea 
and vomiting’ in their Summary of Product Characteristics (eMC).  
Oral solutions of haloperidol are potentially more usable than solid dosage forms in 
palliative care but the volumes involved are very small, need to be measured with an oral syringe 
and solutions of different strengths may lead to confusion and dosing errors. ‘Melt in mouth’ 
(orodispersible) formulations may be of value but there are no published data on whether and 
how such formulations might be used in clinical practice
26
. Transdermal patches have also been 
suggested to both provide a continuous low dose which might diminish side effects
27
. 
 
Conclusions 
There is limited evidence within cancer chemotherapy and post-operative contexts to support 
haloperidol as an antiemetic, with a number needed to treat (NNT) of 3 to 5. However, 
haloperidol at doses of 1-4 mg daily appears to be equivalent to ondansetron in PONV, and 
combinations of haloperidol with either ondansetron or dexamethasone appear to be superior to 
either alone in this context. 
 There remains insufficient evidence from randomised controlled trials to definitively 
support the use of haloperidol for the management of nausea and vomiting in palliative care. 
However, generalising evidence from other contexts (e.g. PONV) may have some validity. 
Observational studies in palliative care that found a complete response rate of 24% (1 in 4 
patients)
24
 would be consistent with an NNT of 3 to 5 derived from PONV (i.e. between 1 in 3 
and 1 in 5 patients achieve a complete response)
13
. This supports the use of haloperidol as an 
effective antiemetic for chemical and metabolic causes of nausea and vomiting, including opioid-
induced nausea, renal failure, and hypercalcaemia. The current range of available formulations of 
haloperidol is not well suited to patients’ needs in the palliative care context.  Novel dosage 
forms could overcome these challenges in the future.   
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